ELAN (6099) FY2026 Q2 Earnings Report

Quick View

Executive Summary

In addition to increases in revenue and earnings, operating leverage from improved gross margin and restrained SG&A expenses resulted in Operating Income expanding at a pace exceeding the revenue growth rate. Revenue was ¥295.3B (¥268.4B in the previous year, YoY+10.0%), Operating Income was ¥26.4B (¥20.6B, YoY+28.3%), and Ordinary Income was ¥25.9B (¥20.3B, YoY+27.5%). Consolidated Net Income was ¥17.3B (¥13.8B, YoY+25.7%), of which Net Income attributable to owners of the parent was ¥17.4B (¥13.7B, YoY+27.2%). Earnings per share was ¥28.74 (¥22.61 in the previous year, YoY+27.1%). The primary reason earnings growth exceeded revenue growth was that the gross margin improved by 1.1pt to 22.6% (21.5% in the previous year), while the SG&A ratio declined slightly to 13.7% (13.8%).

Factors Affecting Performance

【Revenue】Revenue was ¥295.3B, representing YoY+10.0% growth. The Company operates primarily as a single business in the nursing care and medical-related sector. Although revenue by segment has not been disclosed because the importance of other segments is limited, expansion of the core business appears to have driven the increase in revenue.

【Profit and Loss】Operating Income was ¥26.4B, increasing YoY+28.3% and substantially exceeding the revenue growth rate. The gross margin improved by 1.1pt from 21.5% in the previous year to 22.6%, while the SG&A ratio declined slightly to 13.7% from 13.8%, resulting in a 1.2pt improvement in the Operating Income margin from 7.7% to 8.9%. Ordinary Income was ¥25.9B (YoY+27.5%). Factors reducing Operating Income included equity-method investment losses of ¥0.9B, foreign exchange losses of ¥0.1B, and interest expenses of ¥0.3B, partially offset by interest income of ¥0.4B. Consolidated Net Income was ¥17.3B (YoY+25.7%), while the portion attributable to owners of the parent was ¥17.4B (YoY+27.2%). The effective income tax burden was approximately 33%, virtually unchanged from approximately 32% in the previous year. Overall, the results reflect increases in both revenue and earnings, accompanied by profitability improvement, with earnings growth exceeding revenue growth.

Key Financial Indicators

【Profitability】The Operating Income margin improved by 1.2pt to 8.9% from 7.7% in the previous year, while the Net Income margin also increased to 5.9%. ROE was 11.0%, rising primarily as a result of the improvement in the Net Income margin.【Cash Flow Quality】The Company secured Operating Cash Flow (OCF) of ¥18.5B, equivalent to 1.06 times consolidated Net Income, indicating broadly consistent accounting earnings and cash generation. However, OCF was limited to 0.66 times EBITDA (approximately ¥27.9B), suggesting that changes in working capital somewhat constrained cash conversion efficiency.【Investment Efficiency】Capital expenditures of ¥3.7B were approximately 2.5 times depreciation expense of ¥1.5B, indicating that funds are being prioritized for growth investment. Property, plant and equipment increased substantially by +99.4% year on year, making progress in investment recovery a key focus going forward.【Financial Soundness】The Equity Ratio was 58.1% (54.3% in the previous year), while the current ratio was 164.4% and the quick ratio was 150.0%, maintaining ample liquidity. Interest-bearing debt was small relative to total assets, and the financial foundation remained conservative.

Cash Flow Analysis

OCF was ¥18.5B, increasing YoY+16.5% from ¥15.8B in the previous year and equivalent to 1.06 times consolidated Net Income of ¥17.3B. In terms of working capital, the decrease in inventories contributed positively by +¥2.9B, while the increase in trade receivables of -¥3.0B and the decrease in trade payables of -¥3.4B reduced cash conversion. After deducting ¥8.6B in income taxes paid, OCF was compressed from the subtotal of ¥27.0B to ¥18.5B. Investing Cash Flow was -¥3.7B, all of which represented capital expenditures, consistent with the increase in property, plant and equipment (+99.4% year on year). Financing Cash Flow was -¥9.5B, with dividend payments of ¥9.1B representing the primary outflow. As a result, free cash flow (OCF + Investing Cash Flow) was positive at ¥14.7B, a sufficient level to cover dividends and capital expenditures.

Quality of Earnings

The adjustments from Operating Income to Ordinary Income were primarily high non-recurring items, including equity-method investment losses of ¥0.9B, foreign exchange losses of ¥0.1B, and interest expenses of ¥0.3B. Accordingly, the improvement in the Operating Income margin (7.7%→8.9%), which reflects the earning power of the core business, is considered to be structurally driven. Non-operating income was primarily interest income of ¥0.4B and was small in scale. The difference between Ordinary Income and Operating Income was mainly attributable to the equity-method loss on the non-operating expense side. Comprehensive Income was ¥18.1B, and the difference from consolidated Net Income of ¥17.3B was primarily due to foreign currency translation adjustments of +¥0.8B. This reflects valuation differences arising from the translation of overseas-related assets into yen and does not distort the underlying profitability of the core business.

Earnings Forecast and Guidance

Against the full-year Company forecasts of Revenue of ¥608.0B, Operating Income of ¥50.0B, Ordinary Income of ¥50.0B, and Net Income attributable to owners of the parent of ¥32.0B, progress as of the first half was 48.6% for Revenue, 52.8% for Operating Income, 51.8% for Ordinary Income, and 54.3% for Net Income. Each was around or above the approximately 50% benchmark for the first half, with progress on profit indicators, particularly, ahead of revenue progress. No revisions were made to the earnings or dividend forecasts in these results. Whether the improvement in first-half profitability can be maintained from the second half onward will be key to achieving the full-year targets.

Shareholder Returns

The interim dividend was zero (¥0), while the full-year dividend forecast is ¥16, with a year-end lump-sum dividend payment planned. The Payout Ratio against the full-year EPS forecast of ¥52.81 is approximately 30.3%. First-half free cash flow of ¥14.7B exceeded dividend payments during the period of ¥9.1B. Together with the current low-leverage financial structure, this indicates a stable ability to secure funds for dividends.

Risk Factors

1. Working Capital Fluctuations and Cash Conversion Efficiency: During the first half, trade receivables increased by ¥3.0B and trade payables decreased by ¥3.4B, limiting OCF to 0.66 times EBITDA. Seasonal fluctuations in inventories and payment and collection terms could affect cash flow from the second half onward.

2. Factors Affecting Non-Operating Income and Expenses: Equity-method investment losses of ¥0.9B and foreign exchange losses of ¥0.1B reduced Ordinary Income. Because these items have limited correlation with operating performance, the range of future fluctuations in Ordinary Income may vary depending on the performance of equity-method affiliates and foreign exchange trends.

3. Dependence on Nursing Care and Medical-Related Regulations: The Company’s principal business is in the nursing care and medical-related sector, which has industry characteristics whereby regulatory changes, including revisions to medical service fees and nursing care fees, may affect gross margins and demand trends.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Profitability is below the industry median and is positioned near the lower bound of the IQR.

Growth and Capital Efficiency

The revenue growth rate is also below the industry median and is below the lower bound of the IQR.

※Source: Compiled by the Company

Key Takeaways from the Results

1. Operating Income growth of +28.3%, exceeding revenue growth of +10.0%, indicates the emergence of operating leverage resulting from gross margin improvement (22.6%, +1.1pt) and a decline in the SG&A ratio, demonstrating a qualitative improvement in the earnings structure.

2. First-half progress against the full-year guidance was 52.8% for Operating Income and 54.3% for Net Income, exceeding revenue progress of 48.6%, indicating that profit progress is ahead.

3. OCF was limited to 0.66 times EBITDA. Although free cash flow itself was positive at ¥14.7B, the working capital burden from the increase in trade receivables and decrease in trade payables has constrained cash conversion efficiency and requires monitoring from a cash flow quality perspective.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥352–¥373 at Cost of Equity ±1%, and ¥360–¥366 at ω±0.1.

Notes:

• Goodwill amortization of ¥2.0 per share has been added back to earnings (to account for a non-cash expense and comparability with IFRS companies).
• Net assets as of the quarter-end have been used (there is a timing difference relative to the full-year forecast).
• Because non-controlling interests are included in net assets, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q2 was a strong first-half result, with double-digit sales growth translating into materially faster operating and net-profit growth. Revenue increased 10.0% YoY to ¥29.53bn. Operating income rose 28.3% YoY to ¥2.64bn. Ordinary income increased 27.5% YoY to ¥2.59bn. Net income attributable to owners increased 27.2% YoY to ¥1.74bn. The operating margin expanded to 8.9% from 7.7% a year earlier, an improvement of approximately 127bp. Gross margin improved to 22.6% from 21.5%, a gain of approximately 111bp. Net margin rose to 5.9% from 5.1%, improving by approximately 80bp. The widening gap between 10.0% revenue growth and 28.3% operating-income growth indicates favorable operating leverage and/or improved gross-profit economics. SG&A increased 9.0% YoY to ¥4.04bn, slower than revenue growth, supporting the margin expansion. Ordinary income was only ¥0.05bn below operating income, indicating that core operating earnings remained the principal driver of profitability. Operating cash flow was ¥1.85bn, exceeding net income of ¥1.74bn for an OCF/net-income ratio of 1.06x. Free cash flow was positive at ¥1.47bn after ¥0.37bn of capital expenditure. However, cash conversion measured against EBITDA was 0.66x, below the 0.7x quality-alert threshold and requiring monitoring despite OCF exceeding net income. The balance sheet remains liquid, with a 164.3% current ratio, ¥7.38bn of cash and deposits, and only ¥0.56bn of interest-bearing debt. First-half operating-income progress reached 52.8% of the full-year forecast, ahead of the standard 50% Q2 benchmark by 2.8 percentage points. Management has retained its full-year forecast of ¥60.80bn in revenue, ¥5.00bn in operating income, and ¥3.20bn in net income attributable to owners, implying a broadly achievable second half if current gross-margin and SG&A discipline are maintained.

Profitability Analysis

The reported annualized DuPont ROE is 22.0%, comprising a 5.9% net profit margin, 2.175x annualized asset turnover, and 1.72x financial leverage. ROE is therefore led primarily by efficient asset utilization and a solid net margin rather than aggressive interest-bearing borrowing. The largest positive operating change was margin expansion: the operating margin increased approximately 127bp YoY to 8.9%, while gross margin increased approximately 111bp to 22.6%. This indicates that most of the operating-margin improvement came from gross-profit expansion, with further support from SG&A growth of 9.0% remaining below revenue growth of 10.0%. The resulting operating leverage was substantial, as operating income grew 28.3% versus 10.0% sales growth. The 8.9% operating margin falls within the stated 8-15% good range, while the 5.9% net margin is also within the 5-10% good range. The five-factor DuPont analysis shows a tax burden of 0.671, reflecting a 33.1% effective tax rate, while the 0.981 interest burden confirms that financing costs have a negligible effect on pre-tax earnings. EBIT margin was 8.9%, consistent with the operating-margin result. EBITDA was ¥2.79bn and the EBITDA margin was 9.4%; EBITDA before JGAAP goodwill amortization was ¥2.85bn. Goodwill amortization of ¥0.06bn represents only about 2.1% of reported EBITDA, so the JGAAP-versus-IFRS goodwill-accounting difference is not material to the earnings interpretation. Sustaining the current margin trajectory depends on retaining gross-margin gains and preventing SG&A growth from exceeding sales growth.

Growth Assessment

Revenue growth of 10.0% YoY to ¥29.53bn is broadly aligned with the full-year revenue-growth forecast of 9.7%. First-half revenue represents 48.6% of the ¥60.80bn full-year target, only 1.4 percentage points below the standard 50% Q2 progress level. Operating income reached 52.8% of the ¥5.00bn full-year target, outperforming the standard progress rate by 2.8 percentage points. Net income attributable to owners reached 54.3% of the ¥3.20bn full-year target, outperforming the standard Q2 pace by 4.3 percentage points. The stronger profit progress than revenue progress reflects first-half margin expansion rather than merely sales timing. The full-year forecast implies second-half revenue of ¥31.28bn and operating income of ¥2.36bn, equivalent to a second-half operating margin of approximately 7.5%. This implied margin is below the first-half 8.9% margin, leaving some forecast cushion if profitability normalizes in the second half. The group operates principally in the nursing-care and medical-related business, making this its core business and concentrating growth exposure in demand conditions, customer adoption, and execution within that market. PPE nearly doubled YoY to ¥2.77bn, indicating a higher fixed-asset base that should be monitored for whether it supports future service capacity and revenue growth. Capex was ¥0.37bn and capex/depreciation was 2.53x, indicating active reinvestment rather than underinvestment. No revision was made to either earnings or dividend guidance, consistent with management retaining confidence in the original full-year plan.

Financial Health

Liquidity is sound. Current assets of ¥17.82bn exceed current liabilities of ¥10.84bn, producing working capital of ¥6.98bn and a current ratio of 164.3%. The quick ratio of 149.9% confirms that liquidity remains strong even before relying on inventory realization. Cash and deposits of ¥7.38bn account for 27.2% of total assets and are substantially above interest-bearing debt of ¥0.56bn. Debt/capital is only 3.4%, debt/EBITDA is 0.20x, and EBITDA interest coverage is 103.77x, all indicating very limited balance-sheet leverage. Interest coverage based on EBIT is also exceptionally high at 98.32x. Total liabilities equal 41.9% of total assets, while total equity is ¥15.77bn and owners' equity is ¥15.35bn. Current liabilities are dominated by accounts payable of ¥8.03bn, rather than short-term borrowings. The maturity profile nevertheless warrants attention because 54.8% of interest-bearing debt is short term, above the 40% quality-alert threshold. The root cause of this refinancing-risk alert is the concentration of the ¥0.56bn debt balance in short-term loans and the current portion of long-term loans. Its practical impact is moderated by cash covering short-term debt by 24.20x and by the strong current and quick ratios; thus, near-term refinancing capacity appears ample, but the maturity mix should remain monitored if funding needs rise. PPE increased by ¥1.38bn, or 99.4% YoY, to ¥2.77bn and now represents 10.2% of total assets, indicating materially increased capital deployment. Long-term loans declined 31.2% YoY to ¥0.25bn, further reducing long-dated financial obligations. Goodwill of ¥1.05bn equals 6.7% of equity and 0.38x EBITDA, well below risk benchmarks and therefore does not currently create a material impairment-risk concentration.

Notable B/S Changes

Property, plant and equipment: +¥1.38bn (+99.4% YoY) to ¥2.77bn - a substantial expansion of the fixed-asset base; monitor utilization, depreciation burden, and return on invested capital. Long-term loans: -¥0.11bn (-31.2% YoY) to ¥0.25bn - reduced long-term borrowing supports the conservative leverage profile, although a majority of remaining debt is short term. Inventories: -¥0.30bn (-16.2% YoY) to ¥1.56bn - inventory is lower than a year earlier and represents a modest 5.7% of assets, although first-half cash flow recorded a period-on-period inventory increase. Goodwill: -¥0.03bn (-2.4% YoY) to ¥1.05bn - goodwill remains limited at 6.7% of equity and 0.38x EBITDA, keeping impairment exposure contained.

Cash Flow Quality

Operating cash flow was ¥1.85bn, 1.06x net income of ¥1.74bn, supporting the conclusion that reported first-half earnings were cash-backed. The accruals ratio was -0.4%, comfortably below the 5% high-quality threshold and consistent with limited adverse accrual build-up. Free cash flow was ¥1.47bn after capital expenditures of ¥0.37bn, demonstrating internal funding capacity for both investment and shareholder distributions. Cash flow from financing activities was an outflow of ¥0.95bn, principally including ¥0.91bn of cash dividends paid. Working-capital movements nevertheless constrained cash generation during the period: trade receivables increased by ¥0.30bn, inventories increased by ¥0.29bn, and trade payables decreased by ¥0.34bn. These movements collectively reduced operating cash conversion and explain why OCF/EBITDA was only 0.66x. The low-cash-conversion quality alert is rooted in EBITDA not converting fully into operating cash during the first half, despite OCF remaining above net income. This is not currently evidence of weak accounting earnings, given the 1.06x OCF/net-income ratio and low accruals ratio, but it increases the importance of monitoring receivable collection, inventory management, and supplier-payment trends. The impact on the investment case is mainly one of reduced flexibility if working-capital outflows persist alongside elevated reinvestment. Capex/depreciation of 2.53x indicates growth-oriented investment; free-cash-flow resilience will depend on operating cash flow continuing to fund this higher investment level.

Dividend Sustainability

The declared Q2 dividend per share is ¥0, while the full-year dividend forecast is ¥16.00 per share. Based on forecast EPS of ¥52.81, the forecast dividend payout ratio is approximately 30.3%. This is comfortably below the 60% sustainability benchmark. The forecast cash dividend requirement is approximately ¥0.97bn, based on 60.6 million issued shares and ¥16.00 DPS. First-half free cash flow of ¥1.47bn already exceeds this indicated full-year cash-dividend amount. First-half cash dividends paid were ¥0.91bn, which were also covered by first-half free cash flow. Retained earnings were ¥14.34bn, providing substantial balance-sheet capacity relative to the expected dividend commitment. The low leverage position and high interest coverage further support dividend capacity. Dividend sustainability is therefore supported by earnings, free cash flow, retained earnings, and liquidity, provided that working-capital cash demands do not become persistently elevated. No dividend forecast revision has been announced.

Risk Assessment

Business risks include The group is concentrated in its nursing-care and medical-related core business, creating exposure to sector-specific demand conditions, reimbursement or regulatory changes, service-quality requirements, and competitive intensity., The first-half earnings outperformance was driven partly by gross-margin expansion and operating leverage; any reversal in procurement economics, pricing, or operating costs could compress the 8.9% operating margin., PPE increased 99.4% YoY to ¥2.77bn. The return on this enlarged asset base depends on timely utilization and revenue generation from the associated investment., Foreign-exchange losses of ¥0.09bn were recorded in non-operating expenses, indicating some sensitivity to currency movements, although the current profit impact is limited..

Financial risks include The short-term debt ratio of 54.8% exceeds the 40% quality-alert threshold, creating a maturity-concentration and refinancing-monitoring issue. The risk is mitigated by cash/short-term debt of 24.20x, debt/EBITDA of 0.20x, and strong liquidity., Cash conversion of 0.66x is below the 0.7x alert threshold. Receivable growth, inventory growth, and a decrease in trade payables reduced first-half conversion of EBITDA into cash., Capex/depreciation of 2.53x indicates an investment phase. While currently covered by positive free cash flow, sustained elevated capex would raise the required level of recurring operating cash generation..

Key concerns include Monitor whether second-half operating margin remains above the approximately 7.5% margin implied by full-year guidance., Monitor trade receivables, inventories, and trade payables for confirmation that the first-half working-capital outflow does not persist., Monitor the funding mix as debt maturities are managed, even though absolute debt is low., Monitor the productivity and returns associated with the sharp expansion in PPE..

Investment Implications

Key takeaways include First-half sales growth of 10.0% converted into operating-income growth of 28.3%, supported by approximately 127bp operating-margin expansion., Annualized ROE of 22.0% is strong and is supported by a 5.9% net margin, 2.175x annualized asset turnover, and moderate financial leverage., First-half operating-income and net-income progress of 52.8% and 54.3%, respectively, are ahead of standard Q2 progress rates versus unchanged full-year forecasts., Cash earnings quality is broadly sound because OCF exceeded net income and accruals were low, although EBITDA cash conversion needs monitoring., The balance sheet has substantial liquidity and minimal absolute leverage, mitigating the significance of the short-term debt maturity concentration., The forecast 30.3% dividend payout ratio appears conservatively funded by forecast earnings and first-half free cash flow..

Metrics to watch include Operating margin and gross margin versus the 8.9% and 22.6% first-half levels, Second-half revenue and operating-income delivery relative to ¥31.28bn and ¥2.36bn implied by full-year guidance, OCF/EBITDA cash conversion, currently 0.66x, Trade receivables, inventories, and trade payables as indicators of working-capital intensity, Capex and PPE utilization following the 99.4% YoY increase in PPE, Short-term debt proportion and cash/short-term-debt coverage.

Regarding relative positioning, The company displays good-range operating and net margins, excellent annualized ROE, strong liquidity, and exceptionally conservative debt-service capacity. Its primary relative strengths are profit growth materially exceeding revenue growth and low leverage; the principal areas requiring confirmation are cash conversion during a period of elevated reinvestment and the durability of first-half margin expansion.